Tests mRNA-2808 in people with relapsed or refractory multiple myeloma
Tests mRNA-2808 for safety in adults with myeloma that returned or stopped responding to treatment.
Plain-language title generated from the registry record
Registry title: A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Key facts
- Where
- Atlanta, Birmingham, Boston, Charlotte, Milwaukee, Nashville, New York, Philadelphia, and San Francisco, United StatesSee the 10 sites
- Phase
- Phase 1/2
Where in United States
- Emory University HospitalAtlanta, United StatesTaking people
- University of Alabama At Birmingham HospitalBirmingham, United StatesTaking people
- Mass General BrighamBoston, United StatesTaking people
- Atrium Health Levine Cancer InstituteCharlotte, United StatesTaking people
- The Medical College of WisconsinMilwaukee, United StatesTaking people
- Sarah Cannon Research InstituteNashville, United StatesTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesTaking people
- Tisch Cancer Institute at Mount SinaiNew York, United StatesTaking people
- Penn MedicinePhiladelphia, United StatesTaking people
- UCSFSan Francisco, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ModernaTX, Inc.
- Trial code
- NCT07116616
- Record updated
- 23 September 2026
- Original description
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).Read full original descriptionShow less
A Phase 1/2, Open-label, Multicenter Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
Inclusion: RRMM with prior exposure to a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD38) monoclonal antibody; Measurable disease defined as at least 1 of the following:; Serum M-protein ≥0.5 grams/deciliter; Urine M-protein ≥200 milligrams (mg)/24-hour; Involved free light chain (FLC) ≥100 mg/liter and an abnormal FLC ratio; Plasmacytoma with a single diameter ≥2 centimeters; Bone marrow plasma cells >30%.
Exclusion: Radiotherapy or cytotoxic chemotherapy within 2 weeks prior to Day 1 (Baseline), except palliative radiotherapy of limited field is permissible within 2 weeks after discussion with the Sponsor medical monitor; Antibody-based immunotherapy (monoclonal antibody, bispecific antibody, antibody drug conjugate) within 21 days prior to Day 1 (Baseline); Proteasome inhibitor therapy or immunomodulatory agent within 14 days prior to Day 1 (Baseline); Autologous hematopoietic cell transplant within 100 days prior to Day 1 (Baseline); Allogeneic hematopoietic cell transplant within 180 days prior to Day 1 (Baseline); Genetically modified adoptive autologous or allogeneic cellular therapy (for example, chimeric antigen receptor T cell, chimeric antigen receptor natural killer) within 12 weeks prior to Day 1 (Baseline); Corticosteroid therapy ≥140 mg prednisone or equivalent cumulative dose within 14 days prior to Day 1 (Baseline); Note: Other inclusion and exclusion criteria may apply; Known central nervous system (CNS) myeloma or clinical signs and symptoms of CNS involvement of myeloma; Active plasma cell leukemia, defined as peripheral blood plasma cells ≥20%.